Genetics

Swiss pharma giant Novartis has brought a gene therapy to market, while an oral drug from Roche could soon gain approval in the U.S. as well.
The global CRISPR And CRISPR-Associated Genes market is valued at US$350 million in 2018 and will reach US$5220 million by the end of 2025, growing at a CAGR of 40.0% during 2019-2025.
The global CRISPR and Cas genes market shows stellar future growth prospects, expanding at a CAGR of 21.2% during the forecast period (2020-2026).
The FDA expects an approval rate of 10-20 cell and gene therapies every year by 2025.
TheGlobal CRISPR And CRISPR-Associated (Cas) Genes market is valued at US$350 million in 2018 and will reach US$5220 million by the end of 2025, growing at a CAGR of 40.0% during 2019-2025.
The CEO of GenScript BioThe FDA has approved four gene and cell therapies recently, which has brought new hope to patients.
The high need for DNA caused by wide adoption of gene therapies and gene vaccines is expected to drive the synthetic biology market to $38.7 billion by 2020 with an annual growth rate of 44.2%.
The global CRISPR And CRISPR-Associated (Cas) Genes market is valued at USD 713.8 million in 2020 is expected to reach USD 7696.7 million by the end of 2026, growing at a CAGR of 40.0% during 2021-2026.
Predicted to grow at a CAGR of 25% during the forecast period, the global CRISPR Technology market is estimated to reach USD 1,715 million by the end of 2023.
The 2018 cell and gene market was valued at more than US$ 1 billion and is expected to grow to approximately US$ 10 billion by 2025, with compound annual growth rate predicted to be more than 36% in the forecast period (2019-2025).
Advances in gene and cell therapy has made hopes for treatments more possible for diseases caused by a single gene mutation, such as Spinal Muscular Atrophy, which now has two treatments approved for clinical use in the United States.
The Food and Drug Administration envisions that, by 2025, it will be reviewing and approving 10 to 20 cell and gene therapies annually.
BioMarin Pharmaceuticals' hemophilia A gene therapy could be on the market in mid-2020, making the question of how to structure reimbursement an immediate concern for payers.
The sustainability of the annuity-based reimbursement model will unlock commercialization potential of gene therapies and achieve revenue of $2 billion by the end of 2020.
The gene therapy field evolved rapidly over the last decade and, b y 2025, the Food and Drug Administration expects to clear for market 10 to 20 cell or gene therapy products annually.
The Food and Drug Administration expects to approve between 10 and 20 gene and cell therapies each year by 2025.
In Japan, CRISPR will reach a market size of US$235.6 Million by the close of the analysis period.
The global CRISPR Technology market is expected to witness high growth during the forecast period.
The global CRISPR And CRISPR-Associated (Cas) Genes market is valued at US$350 million in 2018 and will reach US$5220 million by the end of 2025, growing at a CAGR of 40.0% during 2019-2025.
Two submissions are expected to represent the first time a gene therapy product for any type of hemophilia will be reviewed for marketing authorization by health authorities.
The Global Gene Editing market is expected to see growth rate of 14.8% and may see market size of USD7.83 Billion by 2024.
The world trade market for cell and gene therapies is expected to greater than the $20 billion USD mark by 2025, with an annual growth rate of 21%.
The FDA predicts that by 2025 between 10 and 20 gene or cell treatments will reach the market each year, potentially roiling the US insurance market if costly treatments for hemophilia and muscular dystrophy win approval.

See full forecast

Last updated: 09 August 2020